Here's Why The Medicines Company Jumped 60% in November
Terrific clinical trial data followed by a $9.7 billion buyout offer gave investors lots to be thankful for.
A pharmaceutical company provides innovative, cost effective acute care hospital products to the worldwide hospital marketplace.
Terrific clinical trial data followed by a $9.7 billion buyout offer gave investors lots to be thankful for.
Understanding why can help you identify the next takeout target.
The stock market got off to a solid start in the holiday-shortened week.
Novartis added another key piece to the puzzle over the weekend.
A buyout rumor has investors hopeful.
Clinical data for cholesterol-lowering drug inclisiran looks good.
MDCO earnings call for the period ending September 30, 2019.
The company's flagship cholesterol treatment shows major potential.
Investors should go to the source.
Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.